Jordi Bove Badell I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases. Institutions of which they are part Main researcher Neurodegenerative Diseases Vall Hebron Institut de Recerca Email Jordi Bove Badell Email Institutions of which they are part Main researcher Neurodegenerative Diseases Vall Hebron Institut de Recerca I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.
I received a Pharmacy degree from the University of Barcelona in 1998. In 2003, I got a PhD in Pharmacy (Neurobiology) with cum laude distinction from the same university at the Experimental Neurology Laboratory, Neurological Service of Hospital Clínic de Barcelona-IDIBAPS (Dr. C. Marin/Prof. E. Tolosa). My doctoral thesis shed light on the mechanism of levodopa-induced motor fluctuations in Parkinson's disease. I later joined the laboratory of Dr. Serge Przedborski at Columbia University (New York, USA) as a post-doctoral researcher (2003-2005), working on animal modeling and the role of alpha-synuclein in Parkinson's disease. In 2006 I co-founded the Neurodegenerative Diseases Research Group at Vall d’Hebron Research Institute (VHIR) in the Vall d’Hebron Hospital Campus (Barcelona) with its leader Dr. Miquel Vila. In 2011, I obtained a position as a Miguel Servet Investigator (Instituto de Salud Carlos III, Spain) as a Researcher in the National System of Health, and since then I am one of the principal investigators of the group. The research that I am leading is aimed to elucidate the mechanism of neuron cell death and to determine new therapeutic targets to develop neuroprotective strategies for Parkinson’s disease and other neurodegenerative diseases. I am also interested in establishing presymptomatic biomarkers of Parkinson´s disease. I am currently focused on the role of the adaptive immune system in Parkinson’s disease. Our latest published study suggests that a cytotoxic attack induced by CD8 T lymphocytes initiates the disease.
Research lines Neuronal dysfunction and immune response in Parkinson's disease IP: Jordi Bove Badell Projects Malalties neurodegeneratives IP: Miquel Vila Bover Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Malalties neurodegeneratives , Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 00784 Duration: 01/01/2022 - 30/06/2025 Pendent IP: Jordi Bove Badell Collaborators: David Ramos Vicente, Miriam Izquierdo Sans, Laia Perez Lasarte Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 64800 Reference: FJC2021-047862-I Duration: 01/01/2023 - 31/12/2024 Characterization of the CD8 T cell response in Parkinson’s disease for the development of preventive and therapeutic strategies that halt the progression of the disease: SARS-Cov-2-induced long term-hyposmia as a possible prodromal stage IP: Jordi Bove Badell Collaborators: Miquel Vila Bover, Alejandro Ferré Masó, Oriol de Fabregues-Boixar Nebot, Carles Lorenzo Bosquet, Thais Cuadros Arasa, Antonio Palasi Franco, David Ramos Vicente Funding agency: Instituto de Salud Carlos III Funding: 165770 Reference: PI21/01358 Duration: 01/01/2022 - 30/06/2026 Estudio de la respuesta inmune adaptativa inducida por epítopos derivados de alfa-sinucleína en pacientes con enfermedad de Parkinson: desarrollo de estrategias neuroprotectoras. IP: Jordi Bove Badell Collaborators: Oriol de Fabregues-Boixar Nebot Funding agency: Instituto de Salud Carlos III Funding: 141570 Reference: PI18/01894 Duration: 01/01/2019 - 31/12/2022 Pagination Current page 1 Page 2 Page 3 Page 4 Next page › Last page »
